Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Butensky & Cohen Financial Security Inc.

Butensky & Cohen Financial Security Inc. raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 2.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,248 shares of the medical research company’s stock after buying an additional 312 shares during the period. Butensky & Cohen Financial Security Inc.’s holdings in Amgen were worth $4,235,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Waterloo Capital L.P. purchased a new position in Amgen in the 2nd quarter worth approximately $231,000. Seven Eight Capital LP acquired a new stake in Amgen during the 2nd quarter valued at $845,000. XTX Topco Ltd purchased a new stake in Amgen during the 2nd quarter worth $661,000. Intech Investment Management LLC lifted its holdings in Amgen by 48.9% in the 2nd quarter. Intech Investment Management LLC now owns 53,109 shares of the medical research company’s stock worth $16,594,000 after buying an additional 17,436 shares in the last quarter. Finally, Ieq Capital LLC boosted its position in Amgen by 7.8% in the 2nd quarter. Ieq Capital LLC now owns 51,921 shares of the medical research company’s stock valued at $16,222,000 after buying an additional 3,757 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Stock Performance

AMGN stock opened at $272.11 on Friday. The company has a market capitalization of $146.27 billion, a P/E ratio of 34.84, a PEG ratio of 2.68 and a beta of 0.56. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The company has a 50-day simple moving average of $275.01 and a 200 day simple moving average of $307.49. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.11 by $0.47. The business had revenue of $8.50 billion during the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business’s revenue was up 23.2% on a year-over-year basis. During the same period last year, the firm posted $4.96 earnings per share. Sell-side analysts predict that Amgen Inc. will post 19.57 earnings per share for the current fiscal year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be paid a dividend of $2.38 per share. The ex-dividend date is Friday, February 14th. This represents a $9.52 annualized dividend and a yield of 3.50%. This is a boost from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio (DPR) is currently 115.24%.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Robert W. Baird reiterated an “underperform” rating and issued a $215.00 price target on shares of Amgen in a research note on Wednesday, September 25th. Cantor Fitzgerald reiterated an “overweight” rating and set a $405.00 target price on shares of Amgen in a research note on Tuesday, October 22nd. Wells Fargo & Company dropped their price target on shares of Amgen from $335.00 to $280.00 and set an “equal weight” rating for the company in a research note on Friday, January 10th. Redburn Partners reduced their price objective on shares of Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Finally, Piper Sandler Companies reissued an “overweight” rating and issued a $310.00 target price on shares of Amgen in a research report on Thursday, January 2nd. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $314.91.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.